-
Mashup Score: 4
Testicular Cancer, Robotic Postchemotherapy, Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND), IGCCCG classification, minimally invasive techniques for Testicular Cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Impact of ACA on Gender-Affirming Care: Urology Study Insights - Akanksha Mehta & Eric Walton - 7 hour(s) ago
Ruchika Talwar interviews Eric Walton and Akanksha Metha about their study on the impact of legislation on access to gender-affirming care, published in the Gold Journal. The research examines the effects of the Affordable Care Act on insurance coverage for transgender and gender-diverse adults using the MarketScan Commercial Claims database from 2009 to 2022. The study reveals a significant…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Impact of the Affordable Care Act on gender-affirming care: Urology study insights. @akankshamehtamd and @ercwltn joins @RuchikaTalwarMD to discuss their work on the impact of legislation on access to gender-affirming care. #WatchNow on UroToday > https://t.co/EtcCyPn0Hb https://t.co/AWInna04Xs
-
-
Mashup Score: 5
Diane Newman delivers a presentation on pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. She explained that while incontinence initially affects 2-90% of patients, most improve within 2-3 months, though 5-20% may experience ongoing symptoms beyond two years. Newman emphasized the importance of pre-…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Pelvic muscle rehabilitation after radical prostatectomy. @DrDianeNewman discusses pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. #WatchNow on UroToday > https://t.co/4w1elr4CJM https://t.co/9e9jWhtp4A
-
-
Mashup Score: 9Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials - Oliver Sartor - 11 hour(s) ago
Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials. Biographies: Oliver Sartor, MD , Medical Oncologist, Professor of Medicine, Urology and Radiology, Director, Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Zachary Klaassen, MD, MSc , Urologic Oncologist,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#ProstateCancer #QuickTakes #ESMO24. #ARANOTE, #PEACE-3, and #SPLASH trials. Oliver Sartor, MD @MayoClinic joins @zklaassen_md @GACancerCenter to discuss on UroToday > https://t.co/0mQzpPF1k7 https://t.co/Ri8YqA4282
-
-
Mashup Score: 5INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra - 1 day(s) ago
Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial’s design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#INSPIRE trial investigates immunotherapy for molecularly selected advanced #ProstateCancer. @NivenMehra @radboudumc joins @neerajaiims @huntsmancancer to discuss the efficacy of nivo + ipi combination therapy in molecularly selected patients with #mCRPC > https://t.co/Rd6NEgCfjT https://t.co/mn9CZ5cAHo
-
-
Mashup Score: 1Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor - 1 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Rana McKay, MD , Medical Oncologist, Associate Professor of…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Case-based discussion on navigating the evolving landscape of castrate-resistant #ProstateCancer management. Oliver Sartor, MD @MayoClinic joins @DrRanaMcKay @UCSanDiego as part of an independent medical education initiative on UroToday > https://t.co/ygi8XDjAQC @BayerPharma https://t.co/OZG83QZgbB
-
-
Mashup Score: 9Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman - 1 day(s) ago
Amy Pearlman discusses penile traction therapy using the RestoreX device, a second-generation technology designed to address penile length changes after prostate cancer treatment. Dr. Pearlman explains how this device, developed by Dr. Landon Trost at Mayo Clinic, offers advantages over first-generation devices through its dynamic stretching capabilities and shorter required usage times. The…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Traction therapy helps men regain penile length after #ProstateCancer treatment. @AmyPearlman1 joins @DrDianeNewman to discuss penile traction therapy using the #RestoreX device #WatchNow on UroToday > https://t.co/8xXfBinwwe @PathRightMed https://t.co/aHeVGo8aVG
-
-
Mashup Score: 15Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett - 2 day(s) ago
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Phase 3 #CLARIFY trial investigates 64Cu-SAR-bisPSMA PET for improved detection. @drlouiseemmett and @zklaassen_md discuss the diagnostic performance of copper-64 bisPSMA PET-CT in high-risk #PCa patients before radical prostatectomy > https://t.co/hRFvY3NdHE @Clarity_Pharma https://t.co/COhQFTPfAb
-
-
Mashup Score: 4Advances and Challenges in High-Risk CSPC: A Multidisciplinary Approach to Patient Management - Paul Sieber - 2 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Paul Sieber, MD, FACS, Keystone, Urology Specialists, Lancaster, PA Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Chief Medical Officer,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances and challenges in high-risk #CSPC: a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > https://t.co/yx14ySV0XT @BayerPharma https://t.co/3aJQsloW0Q
-
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 2 day(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The current state of treatment implementation for metastatic hormone-sensitive #ProstateCancer in #NorthAmerica. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT discuss on UroToday > https://t.co/VDtUiLis3m https://t.co/zNuUo8rc9H
-
Oncological outcomes following robotic postchemotherapy retroperitoneal lymph node dissection for #TesticularCancer: a worldwide multicenter study. #AuthorCommentary with @alirezaghoreifi and @Hoomandjaladat. #ReadNow on UroToday > https://t.co/1wkYjkftE5 @EurUrolFocus https://t.co/oIpY5wwrpI